Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

Contributed by: PR Newswire

Tags

Acousia-Therapeutics

More Like This

ACOUSIA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 PROHEAR STUDY EVALUATING ACOU085 (INN: BIMOKALNER) FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY

ACOUSIA THERAPEUTICS REACHES 50% PATIENT ENROLLMENT MILESTONE IN PHASE 2 PROHEAR STUDY

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Inner hair cells in the inner ear (picture: Nemes Laszlo/Shutterstock.com)

Sudden Hearing Loss: AudioCure's Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS

Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr Ingeborg Hochmair (CEO MED-EL) and Dr Christian Kannemeier (Senior Investment Manager HTGF). Copyright: AudioCure.

InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy

Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study

PR Newswire associated0

Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children